Dr. Ronald Rosmy discussed the current and future impact of AI in healthcare, noting that while immediate benefits may be seen in operational efficiencies, significant advancements in medical research and drug development will take time to materialize. He emphasized the importance of strong business cases and data considerations for effectively integrating AI into the healthcare system.
In a recent discussion, Dr. Ronald Rosmy, a cardiologist and co-founder of Zoy Capital, shared insights on the impact of artificial intelligence (AI) in healthcare. He acknowledged that while AI has begun to be adopted in various medical applications, its actual impact has been minimal thus far. Dr. Rosmy emphasized that the transformative potential of AI in healthcare, particularly in medical research and drug development, will take time to materialize, possibly spanning decades. He agreed with Jamie Dimon’s assertion that AI could eventually lead to breakthroughs like curing cancer, but he cautioned that such advancements are not imminent.
Dr. Rosmy highlighted that the most immediate applications of AI in healthcare are likely to be in administrative and operational areas. He pointed out that healthcare delivery is resource-intensive and often bogged down by bureaucracy. By leveraging AI technology, healthcare providers can streamline operations, improve accessibility, and enhance the quality of care. He noted that basic clinical applications, particularly in fields like radiology, pathology, and dermatology, are where AI can make a significant impact in the short term.
The conversation also touched on the challenges faced in drug development using AI. Dr. Rosmy explained that while there have been promising applications in drug discovery, many investors have been disappointed due to the longer-than-expected timelines for results. He mentioned that Zoy Capital was founded to explore why AI had not gained traction in healthcare, particularly in drug discovery, and concluded that the technology is still not ready for widespread implementation.
Despite the hurdles, Dr. Rosmy expressed optimism about the future of AI in transforming the medical industry. He acknowledged that not every AI application would see immediate adoption, but he believes that with careful analysis and a strong business case, some applications could address critical needs in healthcare. He emphasized the importance of understanding data availability and real-world applicability when developing AI solutions for the medical field.
In summary, Dr. Rosmy’s insights reflect a cautious yet hopeful perspective on the role of AI in healthcare. While immediate benefits may be seen in operational efficiencies, the more ambitious goals of revolutionizing medical research and drug development will require time and careful planning. His emphasis on the need for strong business cases and data considerations underscores the complexities involved in integrating AI into the healthcare system effectively.